- Home
- BLRX vs IMNN Comparison
BLRX vs IMNN Comparison
Compare BLRX & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLRX
- IMNN
- Stock Information
- Founded
- BLRX 2003
- IMNN 1982
- Country
- BLRX Israel
- IMNN United States
- Employees
- BLRX N/A
- IMNN N/A
- Industry
- BLRX Biotechnology: Pharmaceutical Preparations
- IMNN Biotechnology: Pharmaceutical Preparations
- Sector
- BLRX Health Care
- IMNN Health Care
- Exchange
- BLRX Nasdaq
- IMNN Nasdaq
- Market Cap
- BLRX 12.1M
- IMNN 12.1M
- IPO Year
- BLRX 2011
- IMNN 1985
- Fundamental
- Price
- BLRX $5.74
- IMNN $1.46
- Analyst Decision
- BLRX Strong Buy
- IMNN Buy
- Analyst Count
- BLRX 2
- IMNN 2
- Target Price
- BLRX $19.00
- IMNN $14.00
- AVG Volume (30 Days)
- BLRX 2.0M
- IMNN 31.5M
- Earning Date
- BLRX 05-27-2025
- IMNN 05-12-2025
- Dividend Yield
- BLRX N/A
- IMNN N/A
- EPS Growth
- BLRX N/A
- IMNN N/A
- EPS
- BLRX N/A
- IMNN N/A
- Revenue
- BLRX $22,340,000.00
- IMNN N/A
- Revenue This Year
- BLRX N/A
- IMNN N/A
- Revenue Next Year
- BLRX N/A
- IMNN N/A
- P/E Ratio
- BLRX N/A
- IMNN N/A
- Revenue Growth
- BLRX 91.68
- IMNN N/A
- 52 Week Low
- BLRX $2.30
- IMNN $0.37
- 52 Week High
- BLRX $35.60
- IMNN $3.65
- Technical
- Relative Strength Index (RSI)
- BLRX 73.10
- IMNN 52.73
- Support Level
- BLRX $3.88
- IMNN $0.85
- Resistance Level
- BLRX $7.77
- IMNN $3.16
- Average True Range (ATR)
- BLRX 0.75
- IMNN 0.52
- MACD
- BLRX 0.19
- IMNN 0.03
- Stochastic Oscillator
- BLRX 56.81
- IMNN 39.07
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).